CHEK2 antibody (Checkpoint Kinase 2) (AA 481-531)

Details for Product anti-CHEK2 Antibody No. ABIN1724714
Antigen
  • CDS1
  • CHK2
  • HuCds1
  • LFS2
  • PP1425
  • RAD53
  • hCds1
  • fa66f08
  • wu:fa66f08
  • zgc:55865
  • Cds1
  • HUCDS1
  • Rad53
  • Chk2
  • cds1
  • chek2
  • chk2
  • hucds1
  • lfs2
  • pp1425
  • rad53
  • checkpoint kinase 2
  • serine/threonine-protein kinase chk2
  • checkpoint kinase 2 L homeolog
  • CHEK2
  • chek2
  • Chek2
  • MCYG_07308
  • chek2.L
Alternatives
anti-Human CHEK2 antibody for Enzyme Immunoassay
Epitope
AA 481-531
61
53
46
32
26
19
18
17
15
15
13
11
10
9
9
6
6
6
6
5
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Human
526
233
229
23
16
16
13
8
5
4
3
1
1
1
1
1
Host
Mouse
451
77
8
1
1
Clonality (Clone)
Monoclonal ()
Conjugate
This CHEK2 antibody is un-conjugated
16
14
14
14
14
14
14
7
7
5
5
5
5
5
4
2
2
2
2
1
1
Application
Immunocytochemistry (ICC), Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
378
149
142
81
79
66
44
32
25
10
6
3
2
1
Options
Immunogen Purified recombinant fragment of human CHK2 (aa481-531) expressed in E. Coli.
Clone 1C12B8
Isotype IgG2b
Plasmids, Primers & others Plasmids, Primers & others CHEK2 products on genomics-online (e.g. as negative or positive controls)
Antigen
Alternative Name CHK2 (CHEK2 Antibody Abstract)
Background CHK2: CHK2 checkpoint homolog (S. pombe). In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Three transcript variants encoding different isoforms have been found for this gene.
Molecular Weight 61 kDa
Gene ID 11200
HGNC 11200
Pathways p53 Signaling, Apoptosis, Cell Division Cycle
Application Notes ELISA: 1:10000, WB: 1:500 - 1:2000, IHC: 1:200 - 1:1000, ICC: 1:200 - 1:1000
Restrictions For Research Use only
Format Liquid
Buffer Ascitic fluid containing 0.03 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage 4 °C,-20 °C
Storage Comment 4°C, -20°C for long term storage
Supplier Images
Immunocytochemistry (ICC) image for anti-Checkpoint Kinase 2 (CHEK2) (AA 481-531) antibody (ABIN1724714) anti-Checkpoint Kinase 2 (CHEK2) (AA 481-531) antibody
Immunohistochemistry (IHC) image for anti-Checkpoint Kinase 2 (CHEK2) (AA 481-531) antibody (ABIN1724714) anti-Checkpoint Kinase 2 (CHEK2) (AA 481-531) antibody (Image 2)
Western Blotting (WB) image for anti-Checkpoint Kinase 2 (CHEK2) (AA 481-531) antibody (ABIN1724714) anti-Checkpoint Kinase 2 (CHEK2) (AA 481-531) antibody (Image 3)
Product cited in: Cybulski, Masojc, Oszutowska, Jaworowska, Grodzki, Waloszczyk, Serwatowski, Pankowski, Huzarski, Byrski, Górski, Jakubowska, Debniak, Wokolorczyk, Gronwald, Tarnowska, Serrano-Fernández, Lubinski et al.: "Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. ..." in: Carcinogenesis, Vol. 29, Issue 4, pp. 762-5, 2008 (PubMed).

Antoni, Sodha, Collins, Garrett: "CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?" in: Nature reviews. Cancer, Vol. 7, Issue 12, pp. 925-36, 2007 (PubMed).

Bell, Kim, Godwin, Schiripo, Harris, Haserlat, Wahrer, Haiman, Daly, Niendorf, Smith, Sgroi, Garber, Olopade, Le Marchand, Henderson, Altshuler, Haber, Freedman: "Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts." in: International journal of cancer. Journal international du cancer, Vol. 121, Issue 12, pp. 2661-7, 2007 (PubMed).

Did you look for something else?